Adoptive immunotherapy for herpesviruses

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 1318-1331

  Leen, Ann M ^a   Sili, Uluhan ^a   Bollard, Catherine M ^a   Rooney, Cliona M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903252473     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.075     Document Type: Chapter

References (90)

1. Abbas, A. K., Murphy, K. M., and Sher, A. (1996). Functional diversity of helper T lymphocytes. Nature, 383, 787-793.
2. Altman, J. D., Moss, P. A., Goulder, P. J. et al. (2001). Phenotypic analysis of antigen-specific T lymphocytes. Science, 274, 94-96.
3. Amyes, E., Hatton, C., Montamat-Sicotte, D., et al. (2003). Charac-terization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med., 198(6), 903-911.
4. Asanuma, H., Sharp, M., Maecker, H. T., Maino, V. C., and Arvin, A. M. (2000). Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J. Infect. Dis., 181, 859-866.
5. Bollard, C. M., Rossig, C., Calonge, M. J. et al. (2002). Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood, 99, 3179-3187.
6. Bollard, C. M., Aguilar, L., Straathof, K. C. et al. (2004). Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J. Exp. Med., 200(12), 1623-1633.
7. Bonini, C., Lee, S. P., Riddell, S. R., and Greenberg, P. D. (2001). Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J. Immunol., 166, 5250-5257.
8. Borysiewicz, L. K. and Sissons, J. G. (1994). Cytotoxic T cells and human herpes virus infections. Curr. Top.Microbiol. Immunol., 189, 123-150.
9. Brodie, S. J., Lewinsohn, D. A., Patterson, B. K. et al. (1999). In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med., 5, 34-41.
10. Brodie, S. J., Patterson, B. K., Lewinsohn, D. A. et al. (2000). HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J. Clin. Invest., 105, 1407-1417.
11. Bunde, T., Kirchner, A., Hoffmeister, B. et al. (2005). Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J. Exp. Med., 201(7), 1031-1036.
12. Chua, D., Huang, J., Zheng, B. et al. (2001). Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer, 94, 73-80.
13. Clark, D. A. (2002). Human herpesvirus 6 and human herpesvirus 7: Emerging pathogens in transplant patients. Int. J. Hematol., 76 Suppl. 2, 246-252.
14. Clark, D. A. and Griffiths, P. D. (2003). Human herpesvirus 6: Rel-evance of infection in the immunocompromised host. Br. J. Haematol., 120, 384-395.
15. Clark, D. A., Emery, V. C., and Griffiths, P. D. (2003). Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hemato-logical patients. Semin. Hematol., 40, 154-162.
16. Cobbold, M., Khan, N., Pourgheysari, B. et al. (2006). Adoptivetrans-fer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202(3), 379-386.
17. Comoli, P., Labirio, M., Basso, S. et al. (2002). Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for preven-tion of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 99, 2592-2598.
18. Coughlin, C. M., Vance, B. A., Grupp, S. A., and Vonderheide, R. H. (2004). RNA-transfected CD40-activated B cells induce func-tional T-cell responses against viral and tumor antigen targets: Implications for pediatric immunotherapy 103(6), 2046-2054.
19. Curtis, R. E., Travis, L. B., Rowlings, P. A. et al. (1999). Risk of lym-phoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood, 94, 2208-2216.
20. d'Amore, E. S., Manivel, J. C., Gajl-Peczalska, K. J. et al. (1991). B-cell lymphoproliferative disorders after bone marrow trans-plant. An analysis of ten cases with emphasis on Epstein-Barr virus detection by in situ hybridization. Cancer, 68, 1285-1295.
21. Dudley, M. E., Wunderlich, J. R., Robbins, P. F. et al. (2002). Cancer regression and autoimmunity in patients after clonal repopu-lation with antitumor lymphocytes. Science, 298, 850-854.
22. Einsele, H., Roosnek, E., Rufer, N., et al. (2002). Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood, 99, 3916-3922.
23. Foster, A. E. and Rooney, C. M. (2006). Improving T cell therapy for cancer, in press. Expert Opin. Biol. Their. 6(3), 215-229.
24. Foster, A. E., Gottlieb, D. J., Marangolo, M. et al. (2003). Rapid, large-scale generation of highly pure cytomegalovirus-specific cyto-toxic T cells for adoptive immunotherapy. J. Hematother. Stem Cell Res., 12, 93-105.
25. Gahn, B., Siller-Lopez, F., Pirooz, A. D. et al. (2001). Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int. J. Cancer, 93, 706-713.
26. Gottschalk, S., Ng, C. Y., Perez, M., et al. (2001). An Epstein-Barr virus deletion mutant associated with fatal lymphoprolifera-tive disease unresponsive to therapy with virus-specific CTLs. Blood, 97, 835-843.
27. Gottschalk, S., Edwards, O. L., Sili, U. et al. (2003). Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood, 101, 1905-1912.
28. Hale, G. and Waldmann, H. (1998). Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood, 91, 3079-3083.
29. Haque, T., Amlot, P. L., Helling, N. et al. (1998). Reconstitution of EBV-specific T cell immunity in solid organ transplant recipi-ents. J. Immunol., 160, 6204-6209.
30. Heslop, H. E. and Rooney, C. M. (1997). Adoptive cellu-lar immunotherapy for EBV lymphoproliferative disease. Immunol. Rev., 157, 217-222.
31. Heslop, H. E., Li, C., Krance, R. A., Loftin, S. K., and Rooney, C. M. (1994). Epstein-Barr infection after bone marrow transplanta-tion. Blood, 83, 1706-1708.
32. Hislop, A. D., Annels, N. E., Gudgeon, N. H., Leese, A. M., and Rickin-son, A. B. (2002). Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med., 195, 893-905.
33. Jondal, M., Schirmbeck, R., and Reimann, J. (1996). MHC class I-restricted CTL responses to exogenous antigens. Immunity, 5, 295-302.
34. Junghanss, C., Boeckh, M., Carter, R. A. et al. (2002). Incidence and outcome of cytomegalovirus infections following non-myeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood, 99, 1978-1985.
35. Keever-Taylor, C. A., Margolis, D., Konings, S. et al. (2001). Cytomegalovirus-specific cytolytic T-cell lines and clones gen-erated against adenovirus-pp65-infected dendritic cells. Biol. Blood Marrow Transpl., 7, 247-256.
36. Kern, F., Faulhaber, N., Frommel, C. et al. (2000). Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping. Eur. J. Immunol. 30(6), 1676-1682.
37. Khanna, R., Bell, S., Sherritt, M. et al. (1999). Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoprolif-erative disease. Proc. Natl Acad. Sci. USA, 96, 10391-10396.
38. Kuehnle, I., Huls, M. H., Liu, Z. et al. (2000). CD20 monoclonal anti-body (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood, 95, 1502-1505.
39. Lanzavecchia, A. (1996). Mechanisms of antigen uptake for presen-tation. Curr. Opin. Immunol., 8, 348-354.
40. Leen, A., Ratnayake, M., Foster, A., Ahmed, N., Rooney, C. M. and Gottschalk, S. (2006a). Contact activated Monocytes: Efficient antigen presenting cells for the stimulation of antigen-specific T cells. J. Immunother. (in press)
41. Leen, M., Myers, G. D., Sili, U. et al. (2006b). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised patients. Nature Med., Nat. Med., 12(10), 1160-1166.
42. Levine, A. M., Seneviratne, L., and Tulpule, A. (2001). Incidence and management of AIDS-related lymphoma. Oncology (Hunt-ingt), 15, 629-639.
43. Li, H. and Minarovits (2003). Host cell-dependent expression of latent Epstein-Barr virus genomes: Regulation by DNA methy-lation. J. Adv. Cancer Res. 89, 133-156.
44. Lucas, K. G., Sun, Q., Burton, R. L. et al. (2000). A phase I-II trial to examine the toxicity of CMV-and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther., 11, 1453-1463.
45. Maus, M. V., Thomas, A. K., Leonard, D. G. et al. (2002). Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol., 20, 143-148.
46. McMichael, A. (1998). T cell responses and viral escape. Cell, 93, 673-676.
47. Melenhorst, J. J., Solomon, S. R., Shenoy, A. et al. (2006). Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J. Immunother., 29(4), 436-443.
48. Michaelides, A., Glare, E. M., Spelman, D. W. et al. (2002). beta-Herpesvirus (human cytomegalovirus and human herpesvirus 6) reactivation in at-risk lung transplant recipients and in human immunodeficiency virus-infected patients. J. Infect. Dis., 186, 173-180.
49. Miyashita, E. M., Yang, B., Babcock, G. J., and Thorley-Lawson, D.A. (1997). Identification of the site of Epstein-Barr virus persis-tence in vivo as a resting B cell. J. Virol., 71, 4882-4891.
50. Mocarski, E. S. and Courcelle, C. (2001). Cytomegaloviruses and their replication. In Knipe, D. M. and Howley, P. M. eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, pp. 2629-2673.
51. Nguyen, Q., Champlin, R., Giralt, S. et al. (1999). Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin. Infect. Dis., 28, 618-623.
52. Niedobitek, G. (2000). Epstein-Barr virus infection in the patho-genesis of nasopharyngeal carcinoma. Mol. Pathol., 53, 248-254.
53. Oelke, M., Maus, M. V., Didiano, D. et al. (2003). Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med., 9, 619-624.
54. Pamer, E. and Cresswell, P. (1998). Mechanisms of MHC class I-restricted antigen processing. Annu. Rev. Immunol., 16, 323-358.
55. Pao, W. J., Hustu, H. O., Douglass, E. C., Beckford, N. S., and Kun, L. E. (1989). Pediatric nasopharyngeal carcinoma: Long term follow-up of 29 patients. Int. J. Radiat. Oncol. Biol. Phys., 17, 299-305.
56. Papadopoulos, E. B., Ladanyi, M., Emanuel, D. et al. (1994). Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med., 330, 1185-1191.
57. Park, K. D., Marti, L., Kurtzberg, J. and Szabolcs, P. (2006). In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood, 108(5), 1770-1773.
58. Pass, R. (2001). Cytomegalovirus. In Knipe, D. M. and Howley, P. M. eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, pp. 2675-2705.
59. Peggs, K. S., Verfuerth, S., Pizzey, A. et al. (2003). Adoptive cel-lular therapy for early cytomegalovirus infection after allo-geneic stem-cell transplantation with virus-specific T-cell lines. Lancet, 362, 1375-1377.
60. Qu, L. and Rowe, D. T. (1992). Epstein-Barr virus latent gene expres-sion in uncultured peripheral blood lymphocytes. J. Virol., 66, 3715-3724.
61. Razonable, R. R. and Paya, C. V. et al. (2003). Herpesvirus infections in transplant recipients: Current challenges in the clinical man-agement of cytomegalovirus and Epstein-Barr virus infections. Herpes., 10(3), 60-65.
62. Rickinson, A. B. and Kieff, E. (2001). Epstein-Barr virus. In Knipe, D. M. and Howley, P. M., eds. Fields Virology. Philadelphia, PA: Lippincott Williams + Wilkins, pp. 2575-2628.
63. Rickinson, A. B. and Moss, D. J. (1997). Human cytotoxic T lym-phocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol., 15, 405-431.
64. Riddell, S. R., Elliott, M., Lewinsohn, D. A. et al. (1996). T-cell medi-ated rejection of gene-modified HIV-specific cytotoxic T lym-phocytes in HIV-infected patients. Nat. Med. 2, 216-223.
65. Rooney, C. M., Loftin, S. K., Holladay, M. S. et al. (1995a). Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br. J. Haematol., 89, 98-103.
66. Rooney, C. M., Smith, C. A., Ng, C. Y. et al. (1995b). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet, 345, 9-13.
67. Rooney, C. M., Roskrow, M. A., Suzuki, N. et al. (1998a). Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann. Oncol., 9, Suppl 5, S129-S132.
68. Rooney, C. M., Smith, C. A., Ng, C. Y. et al. (1998b). Infusion of cyto-toxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92, 1549-1555.
69. Rooney, C. M., Aguilar, L. K., Huls, M. H., Brenner, M. K., and Hes-lop, H. E. (2001). Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr. Top. Microbiol. Immunol., 258, 221-229.
70. Rooney, C. M., Bollard, C., Huls, M. H. et al. (2002). Immunotherapy for Hodgkin's disease. Ann. Hematol., 81 Suppl 2, S39-S42.
71. Roskrow, M. A., Suzuki, N., Gan, Y. et al. (1998). Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood, 91, 2925-2934.
72. Savoldo, B., Goss, J. A., Hammer, M. M. et al. (2006). Treatment of solid organ transplant recipients with autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (CTL). Blood., Epub ahead of print.
73. Savoldo, B., Goss, J., Liu, Z. et al. (2001). Generation of autolo-gous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Trans-plantation, 72, 1078-1086.
74. Savoldo, B., Cubbage, M. L., Durett, A. G. et al. (2002). Generation of EBV-specific CD4+ cytotoxic T cells from virus naive indi-viduals. J. Immunol., 168, 909-918.
75. Sigal, L. J., Crotty, S., Andino, R., and Rock, K. L. (1999). Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells re-quires presentation of exogenous antigen. Nature, 398, 77-80.
76. Sili, U., Huls, M. H., Davis, A. R. et al. (2003). Large-scale expan-sion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J. Immunother., 26, 241-256.
77. Springer, K. L., Chou, S., Li, S. et al. (2005). How evolution of muta-tions conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J. Clin. Microbiol., 43(1), 208-213.
78. Stevens, S. J., Verschuuren, E. A., Pronk, I. et al. (2001). Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood, 97, 1165-1171.
79. Straathof, K. C., Savoldo, B., Heslop, H. E., and Rooney, C. M. (2002). Immunotherapy for post-transplant lymphoproliferative dis-ease. Br. J. Haematol., 118, 728-740.
80. Straathof, K. C., Bollard, C. M., Popat, U. et al. (2005). Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood, 105(5), 1898-1904.
81. Sun, Q., Pollok, K. E., Burton, R. L. et al. (1999). Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood, 94, 3242-3250.
82. Sun, Q., Burton, R. L., Dai, L. J., Britt, W. J., and Lucas, K. G. (2000). B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen. J. Immunol., 165, 4105-4111.
83. Szmania, S., Galloway, A., Bruorton, M. et al. (2001). Isola-tion and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood, 98, 505-512.
84. Tierney, R. J., Steven, N., Young, L. S., and Rickinson, A. B. (1994). Epstein-Barr virus latency in blood mononuclear cells: Analy-sis of viral gene transcription during primary infection and in the carrier state. J. Virol., 68, 7374-7385.
85. van Esser, J. W., Niesters, H. G., van der, H. B. et al. (2002). Pre-vention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood, 99, 4364-4369.
86. Vaz-Santiago, J., Lule, J., Rohrlich, P. et al. (2002). IE1-pp65 recombi-nant protein from human CMV combined with a nanopartic-ulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy. Cytotherapy, 4, 11-19.
87. Wagner, H. J., Sili, U., Gahn, B. et al. (2003). Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: Influence of recombinant IL12 and IL15. Cytotherapy, 5, 231-240.
88. Walter, E. A., Greenberg, P. D., Gilbert, M. J. et al. (1995). Reconstitu-tion of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med., 333, 1038-1044.
89. Wang, Q. J., Jenkins, F. J., Jacobson, L. P. et al. (2000). CD8+ cyto-toxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type 1-infected and-uninfected individuals. J. Infect. Dis., 182, 928-932.
90. Weinberg, K., Blazar, B. R., Wagner, J. E. et al. (2001). Factors affect-ing thymic function after allogeneic hematopoietic stem cell transplantation. Blood, 97, 1458-1466.